ZoBio Launches DEL Platform to Accelerate Drug Discovery for Challenging Molecular Targets

ZoBio's rollout of a DNA-encoded library (DEL) platform signals a shift in how early-stage discovery programs may approach historically intractable targets — a development with direct implications for research teams managing hit identification timelines and candidate attrition rates.

DEL technology enables simultaneous screening of millions of compounds against a target protein by encoding each compound with a unique DNA tag, allowing rapid identification of binders without the throughput constraints of conventional high-throughput screening. For discovery organizations operating under compressed development timelines, the platform offers a route to hit matter on targets where standard small-molecule approaches have repeatedly stalled.

ZoBio, a Netherlands-based contract research organization with an established fragment-based drug discovery practice, positions the DEL capability as complementary to its existing biophysical and structural biology toolkit. The integration is operationally relevant: programs that exhaust fragment screening options can transition into DEL-based hit finding within the same CRO relationship, reducing handoff risk and preserving structural data continuity across the discovery arc.

For medicinal chemistry and biology leads evaluating external discovery partnerships, the practical question is how DEL library diversity and encoding fidelity hold up against validated internal benchmarks. ZoBio has not disclosed library size or the range of target classes covered at launch, details that will bear on how quickly the platform can be stress-tested against real program needs.

The broader context is a competitive DEL services market that has expanded considerably since Encoded Library Technologies (ELT) demonstrated the approach's commercial viability; established players including HitGen and X-Chem have built substantial library collections over multiple years. ZoBio's differentiation will likely rest on the depth of its structural follow-up capabilities rather than library scale alone.

Initial platform performance data across a defined set of target classes will be the clearest indicator of where the offering fits within a tiered external discovery strategy.

Source: Indian Pharma Post via Media4Growth, 14 June 2026.